Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial

INTRODUCTION: The objective of this study was to investigate the effect of adding exenatide to continuous subcutaneous insulin infusion (CSII) therapy on the precise insulin doses required by type 2 diabetic patients to maintain glycemic control. METHODS: This was a single-center, randomized, contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Feng-fei, Jiang, Lanlan, Fu, Liyuan, Zhu, Hong-hong, Zhou, Peihua, Zhang, Danfeng, Su, Xiao-fei, Wu, Jin-dan, Ye, Lei, Ma, Jian-hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306121/
https://www.ncbi.nlm.nih.gov/pubmed/27995593
http://dx.doi.org/10.1007/s13300-016-0222-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306121/
https://www.ncbi.nlm.nih.gov/pubmed/27995593
http://dx.doi.org/10.1007/s13300-016-0222-7

Ejemplares similares